$18.10
-0.18 (-0.98%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where ERAS is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
9 interventional
Held by 17 tracked-famous managers (RENAISSANCE TECHNOLOGIES LLC, Point72 Asset Management, L.P., D. E. Shaw & Co., Inc., MILLENNIUM MANAGEMENT LLC, MARSHALL WACE, LLP, +12 more) · FINRA short interest 7.3 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.NCT07021898Dose Limiting Toxicities (DLT)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: ERAS-4001, ERAS-4001 in combination | Metastatic Solid Tumors | 200 | Aug 2028 | ≤ 743 d | 2025-12-03 |
| A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid TumorsNCT06983743Dose Limiting Toxicities (DLT)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: ERAS-0015, ERAS-0015 in combination | Metastatic Solid Tumors | 600 | 2028-05-01 | in 621 d | 2026-07-31 |
| A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)NCT06346067Stage 1:To select the optimal dose of naporafenib + trametinib to be studied in Stage 2Randomized · Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: Naporafenib, Dacarbazine, Temozolomide, Trametinib | Advanced or Metastatic NRAS-mutant Melanoma | 78 | Apr 2028 | ≤ 620 d | 2026-02-27 |
| A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid TumorsNCT04866134Evaluate safety and tolerability of escalating doses of ERAS-007 BID-QWNon-randomized · Open-label · Treatment | Phase 1/2 | Active, not recruiting | Drug: ERAS-007, ERAS-601 | Advanced or Metastatic Solid Tumors | 200 | 2026-11-01 | in 74 d | 2026-06-22 |
| A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid TumorsNCT04670679Dose Limiting Toxicities (DLT)Non-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: ERAS-601, Cetuximab, Pembrolizumab | Advanced or Metastatic Solid Tumors | 90 | 2026-02-01actual | — | 2026-03-25 |
| A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X MutationsNCT05907304To evaluate the efficacy of naporafenib administered with trametinib in patients with rat sarcoma viral oncogene (RAS) Q61X solid tumorsOpen-label · Treatment | Phase 1 | Active, not recruiting | Drug: Naporafenib, Trametinib | Advanced or Metastatic Solid Tumors | 86 | 2025-07-01actual | — | 2026-02-27 |
| A Study of ERAS-007 in Patients With Advanced Gastrointestinal MalignanciesNCT05039177Dose Limiting Toxicities (DLT)Non-randomized · Open-label · Treatment | Phase 1/2 | Completed | Drug: ERAS-007, Encorafenib, Cetuximab, Palbociclib | Metastatic Colorectal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma | 101 | 2025-08-15actual | — | 2026-03-25 |
| A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic MalignanciesNCT05279859Dose Limiting Toxicities (DLT)Non-randomized · Open-label · Treatment | Phase 1/2 | Withdrawnsponsor's stated reason: Sponsor decision. | Drug: ERAS-007, ERAS-601, Gilteritinib | Acute Myeloid Leukemia | 0 | 2025-03-01 | — | 2022-06-15 |
| A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLCNCT04959981Dose Limiting Toxicities (DLT)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: ERAS-007, ERAS-601, Osimertinib, Sotorasib | Advanced Non-squamous Non-small-cell Lung Cancer | 24 | 2023-04-27actual | — | 2023-07-25 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19